# OnCo record nct05023980 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05023980/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05023980", "NCT05023980" ;
  schema:name "A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)"@en ;
  schema:alternateName "BRUIN CLL-313"@en ;
  schema:description "A phase 3 trial of Pirtobrutinib, Bendamustine and Rituximab in chronic lymphocytic leukaemia, run by Loxo Oncology, Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05023980/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05023980> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2021-09-23" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/cll-treatment-naive/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/rituximab/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> .